Equity Profile

VCYT

VERACYTE INC

Health CareBiotechnology$3.9B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Veracyte Beats on EPS, Stock Down 1.43%

Metric	Actual	Expected	Surprise
EPS	$0.52	$0.33	+126.09%
Revenue	—	$130M	—

management commentary, guidance changes, and full analysis available with Pro.

Veracyte Beats on EPS, Stock Down 1.43%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.52	$0.33	+126.09%
Revenue	—	$130M	—

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

What It Means

Veracyte's strong EPS performance significantly exceeded expectations, indicating better-than-expected profitability. However, the stock fell by 1.43%, suggesting that investors may have been disappointed by the lack of revenue data and guidance. The absence of management commentary also leaves uncertainty about future performance.

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and is closely watched by investors.

$0.33

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$130M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics. Operating in the health care sector, Veracyte's tests help physicians make more informed decisions, particularly in cancer diagnosis and treatment, which is increasingly important in today's health landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In the last quarter, Veracyte reported an EPS of $0.53, significantly exceeding expectations. The stock reacted positively, gaining 0.08% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving diagnostic accuracy.
Plans to enhance market penetration in existing and new territories.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Veracyte's upcoming earnings, expecting solid performance based on historical trends.

Bull Case

If Veracyte meets or exceeds the EPS and revenue estimates, it could reinforce investor confidence and lead to a positive stock reaction.

Bear Case

However, if the company fails to meet expectations, particularly after a series of strong earnings surprises, it could lead to a significant sell-off.

Key Metrics to Watch

EPS

$0.33

Earnings per share (EPS) is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$130M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Veracyte's EPS exceed the consensus estimate of $0.33?

Given the company's strong history of earnings surprises, a beat could significantly boost investor sentiment.

What revenue growth can Veracyte report against the consensus of $130M?

Revenue performance is crucial for understanding market demand and the effectiveness of their product offerings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Veracyte's ability to leverage recent product innovations, which could drive higher-than-expected revenue growth.

Supporting Evidence

Veracyte has consistently exceeded EPS estimates, suggesting strong operational execution.

The options market indicates heightened volatility, which may reflect investor anticipation of a significant announcement or update.

Recent insider activity, while routine, could suggest confidence in upcoming performance.

Key Risk

If revenue growth exceeds $135M, it could challenge current market expectations and lead to a reevaluation of the stock's potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's growth trajectory or raise concerns about its market position.

Bull Confirmed If

An EPS of $0.37 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.23 would signal potential issues with market demand or operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±18.46%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a larger-than-average move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±18.5% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.4%

30d HV

50.0%

Calls (7K)P/C Ratio: 0.51Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests a potential stock increase of around +0.33%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a stock decline, with historical patterns indicating a possible drop of around -4.16%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into market demand trends for Veracyte's diagnostic tests.
3Management's commentary on competitive positioning in the biotechnology space.
4Details on operational efficiencies and cost management strategies.
5Guidance on future growth prospects and market expansion plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and is closely watched by investors.

$0.33

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$130M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In the last quarter, Veracyte reported an EPS of $0.53, significantly exceeding expectations. The stock reacted positively, gaining 0.08% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to improving diagnostic accuracy.
Plans to enhance market penetration in existing and new territories.

Expectations

Wall Street Expectations

Analysts are generally optimistic about Veracyte's upcoming earnings, expecting solid performance based on historical trends.

Bull Case

If Veracyte meets or exceeds the EPS and revenue estimates, it could reinforce investor confidence and lead to a positive stock reaction.

Bear Case

However, if the company fails to meet expectations, particularly after a series of strong earnings surprises, it could lead to a significant sell-off.

Key Metrics to Watch

EPS

$0.33

Earnings per share (EPS) is a key indicator of the company's profitability and is closely watched by investors.

Revenue

$130M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Veracyte's EPS exceed the consensus estimate of $0.33?

Given the company's strong history of earnings surprises, a beat could significantly boost investor sentiment.

What revenue growth can Veracyte report against the consensus of $130M?

Revenue performance is crucial for understanding market demand and the effectiveness of their product offerings.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Veracyte's ability to leverage recent product innovations, which could drive higher-than-expected revenue growth.

Supporting Evidence

Veracyte has consistently exceeded EPS estimates, suggesting strong operational execution.

The options market indicates heightened volatility, which may reflect investor anticipation of a significant announcement or update.

Recent insider activity, while routine, could suggest confidence in upcoming performance.

Key Risk

If revenue growth exceeds $135M, it could challenge current market expectations and lead to a reevaluation of the stock's potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's growth trajectory or raise concerns about its market position.

Bull Confirmed If

An EPS of $0.37 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $0.23 would signal potential issues with market demand or operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±18.46%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a larger-than-average move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±18.5% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.4%

30d HV

50.0%

Calls (7K)P/C Ratio: 0.51Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations, history suggests a potential stock increase of around +0.33%, confirming strong operational momentum.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a stock decline, with historical patterns indicating a possible drop of around -4.16%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Insights into market demand trends for Veracyte's diagnostic tests.
3Management's commentary on competitive positioning in the biotechnology space.
4Details on operational efficiencies and cost management strategies.
5Guidance on future growth prospects and market expansion plans.